Dalgard, Olav <br/><br/>
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.  [electronic resource] 

 -  Hepatology (Baltimore, Md.)  Jan 2008 
 - 35-42 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-3350 
<br/><br/><label>Standard No.: </label>10.1002/hep.21975  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C--drug therapy<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Male<br/>Middle Aged<br/>Polyethylene Glycols<br/>Recombinant Proteins<br/>Ribavirin--administration & dosage<br/>Viral Load--statistics & numerical data